BAAT and Lynch syndrome: As of June 2021, it had been approved for the following indications: “assistance in evaluating whether pembrolizumab is indicated in patients with solid tumors,” “assistance in evaluating whether nivolumab is indicated in patients with cancer of the colon or rectum,” “assistance in diagnosing Lynch syndrome in colorectal cancer,” and “assistance in selecting chemotherapy for colorectal cancer.” This test kit adopts a panel consisting of only mononucleotide repeat markers (BAT-25, BAT-26, NR-21, NR-24, and MONO27) (Table 4).